ArticleClinical, cosmetic and investigational dermatology2025
Global and Regional Burden of Seborrheic Dermatitis: Trends in Incidence and DALYs, 1990-2021.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Atopic, seborrheic, and contact dermatitis burden in G20 countries, 1990-2023, with projections to 2050.JAAD international · 2026Article
- Global Burden and Demographic Decomposition of Seborrheic Dermatitis, 1990-2023: A Secondary Analysis of GBD 2023 Estimates.Clinical, cosmetic and investigational dermatology · 2026Article
- Knowledge, Attitudes, and Practices Among Patients with Seborrheic Dermatitis: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Trends and projections of dermatitis burden (1990-2040): a 2021 global burden of disease analysis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Seborrheic dermatitis (SD) is a prevalent chronic skin condition affecting areas rich in sebaceous glands, causing significant discomfort and psychological burden. Despite its impact, detailed global burden trends remain underexplored. Methods: Data from the Global Burden of Disease (GBD) study for SD from 1990 to 2021 were analyzed, examining incidence and Disability-Adjusted Life Years (DALYs). Trends were assessed using the estimated annual percentage change (EAPC), and correlations between disease burden and socio-economic development indices (SDI) were evaluated. Results: In 2021, SD affected 135,710,441 individuals globally-an increase of 53% since 1990. Despite this growth, the global age-standardized incidence rate (ASIR) remained relatively stable at 1,704.04 per 100,000 (EAPC: 0.11183). Females showed a higher ASIR than males, while males had slightly higher age-standardized DALYs rates. The 75+ age group experienced the highest DALYs burden despite the lowest ASIR, highlighting a disproportionate impact on the elderly. Regions with higher SDI levels generally had lower incidence and DALYs rates, whereas Western Sub-Saharan Africa bore the highest burden. Nationally, Nigeria, Ghana, and Cameroon had the highest ASIRs. These findings underscore significant regional and national disparities in SD burden, even amid overall rate stability. Conclusion: Despite stable age-standardized rates, the increasing absolute burden of seborrheic dermatitis and pronounced regional disparities underscore the need for targeted public health interventions, particularly in resource-limited settings. Strengthening disease management strategies and expanding research efforts in these areas will be crucial to reducing the global impact of SD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.